- Company
- ₩200 bil schizophrenia treatment market is changing
- by Kim, Jin-Gu Jan 14, 2022 05:50am
- Change is in the air in the schizophrenia treatment market that was once led by global pharmaceutical companies such as Otsuka Pharmaceutical and Janssen. Domestic companies are acquiring rights of originals and introducing new products to chase the multinational leaders in the market. In response to the change, the global pharmaceutical com
- Policy
- The ultra-high-priced new drug Kymriah passed the Committee
- by Lee, Hye-Kyung Jan 14, 2022 05:50am
- Kymriah(Tisagenlecleucel) of Novartis Korea, dubbed an ultra-high-priced "one-shot treatment" with a cost of 500 million won per dose, passed the committee. The HIRA (Director Kim Sun-min) held the first Drug Reimbursement Evaluation Committee in 2021 on the afternoon of the 13th and conducted a review on the appropriateness of medical care bene
- Policy
- MOHW·MOTIE accelerates Global COVID-19 Vaccine Hub project
- by Kim, Jung-Ju Jan 14, 2022 05:50am
- The Ministry of Health and Welfare (MOHW) and the Ministry of Trade, Industry, and Energy (MOTIE) joined forces to come up with a plan to accelerate the government’s goal of Korea becoming a ‘Global Vaccine Hub’ that was set last year. On the morning of the 13th, Minister of Health and Welfare Kwon Deok-Chul and First Vice Minister of T
- Policy
- COVID-19 vaccine by NovaVax is approved in Korea
- by Lee, Tak-Sun Jan 14, 2022 05:50am
- COVID-19 vaccine by NovaVax was approved for domestic items on the 12th. At the final inspection committee held on the same day, experts judged that the Novavax vaccine had a sufficient effect on preventing COVID-19. The MFDS announced on the 12th that SK Bioscience has decided to approve the product on the condition that it submits a fina
- Company
- One clinical trial of NeoImuneTech's new immuno-cancer drug
- by Ji Yong Jun Jan 14, 2022 05:50am
- NeoImuneTech has suspended one clinical trial for the treatment of COVID-19 of NT-I7 (efineptakin alfa), which is being developed as a new immuno-cancer drug. According to ClinicalTrials.gov operated by NIH in the U.S. on the 12th, it was confirmed that NeoImuneTech withdrew one phase 1 clinical trial related to NT-I7 in the second half of la
- Policy
- The timing of approval for Novavax vaccine is unpredictable
- by Lee, Tak-Sun Jan 13, 2022 02:54pm
- The MFDS, which was active in disclosing information on COVID-19 vaccine screening, is suddenly not disclosing any information on the Novavax vaccine. There was no news of the expert advisory group, and 40 days have already passed the promised screening period. Some analysts say that this is because it is difficult for the MFDS to predict the
- Company
- SK Bioscience, speeding up its development of COVID Vaccine
- by Kim, Jin-Gu Jan 13, 2022 06:05am
- SK Bioscience is speeding up the commercialization of its own COVID-19 vaccine. In particular, it is predicted that the approval of the Novavax vaccine will have a positive effect at a time when the GBP510 is aimed at licensing items in the first half of this year. On the 12th, the MFDS approved Nuvaxovid PFS, NovaVax's COVID-19 vaccine. T
- Company
- A single tech export brings in 11 times the annual revenue
- by Chon, Seung-Hyun Jan 13, 2022 06:05am
- The biotechnology company ABL Bio signed a mega-deal and secured 11 times its annual revenue through a single license agreement. Its upfront payment by itself ranks in the top 5 among the technology export deals made by pharmaceutical and biopharmaceutical companies in Korea. When excluding the ones that have returned the rights, ABL Bio’s deal
- Policy
- NHRC issues ‘expedited listing of Kymriah’ opinion to MOHW
- by Lee, Jeong-Hwan Jan 13, 2022 06:05am
- The National Human Rights Commission of Korea urged the Ministry of Health and Welfare on the need to expedite insurance listing of the CAR-T therapy ‘Kymriah’ that is used to treat leukemia and lymphoma. The NHRC’s position is that the government should set a temporary drug price with NHI coverage for drugs that are directly related t
- Company
- Viatris & J&J hired female executives
- by Eo, Yun-Ho Jan 12, 2022 06:05am
- Executive-level personnel in charge of multinational pharmaceutical's external cooperation department are active. According to related industries, Viatris Korea appointed Kim Ji-young (52 years old), former executive director of Janssen Korea, as the head of the dept. of Foreign Cooperation in December last year, while Johnson & Johnson Korea
